Sepio Capital LP Cuts Position in AbbVie Inc. $ABBV

Sepio Capital LP reduced its holdings in AbbVie Inc. (NYSE:ABBV) by 6.7% during the 4th quarter, Holdings Channel reports. The fund owned 125,915 shares of the company’s stock after selling 9,074 shares during the quarter. AbbVie comprises 1.6% of Sepio Capital LP’s portfolio, making the stock its 10th largest holding. Sepio Capital LP’s holdings in AbbVie were worth $28,770,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Chelsea Counsel Co. acquired a new stake in AbbVie in the 3rd quarter valued at approximately $26,000. Westend Capital Management LLC acquired a new stake in AbbVie in the 4th quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX acquired a new stake in AbbVie in the 3rd quarter valued at approximately $31,000. Legacy Wealth Managment LLC ID increased its position in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after acquiring an additional 73 shares during the period. Finally, WestEnd Advisors LLC increased its position in AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Performance

Shares of ABBV stock opened at $225.04 on Friday. AbbVie Inc. has a 1 year low of $181.73 and a 1 year high of $244.81. The stock has a market cap of $397.60 billion, a PE ratio of 110.86, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32. The business’s fifty day moving average is $210.80 and its 200-day moving average is $219.01.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same period last year, the firm earned $2.46 EPS. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. Equities research analysts predict that AbbVie Inc. will post 14.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on ABBV shares. Morgan Stanley raised their target price on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Evercore set a $235.00 target price on AbbVie in a research report on Friday, May 15th. Guggenheim reiterated a “buy” rating and set a $249.00 price target on shares of AbbVie in a research report on Friday, May 1st. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Monday. Finally, Piper Sandler lifted their price target on AbbVie from $294.00 to $298.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $253.43.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts and media coverage highlighted AbbVie’s Skyrizi and Rinvoq as key growth drivers, noting strong first-quarter performance and the potential for continued sales momentum through 2026, including additional indications. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Positive Sentiment: Another market commentary framed AbbVie as a growth-pharma stock at a value-pharma price, reinforcing the view that its earnings growth and pipeline may justify the valuation. AbbVie: Growth-Pharma Profile At A Value-Pharma Price
• Positive Sentiment: AbbVie was also featured on CNBC’s “Final Trades”, which can support investor sentiment by keeping the stock in the market spotlight. AbbVie, Devon Energy and more on CNBC’s ‘Final Trades’
• Neutral Sentiment: Several pieces described AbbVie as a stock worth watching or holding after a strong run, with valuation and balance-sheet concerns tempering enthusiasm but not signaling a major change in the business outlook. Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225
• Negative Sentiment: AbbVie also faced a FDA Complete Response Letter for its fast-acting neurotoxin TrenibotE, citing manufacturing-related issues. While the letter reportedly raised no safety or efficacy concerns, it delays the program and adds near-term regulatory uncertainty. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.